Overview

Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a null hypothesis study. The investigators hypothesize that there will be no difference in changes in dynamic compliance when measured at 15, 30, 45 and 60 minute intervals after administration of either surfactant and there will be no differences in the number of doses needed between the two surfactants in premature infants admitted to our NICU.
Phase:
N/A
Details
Lead Sponsor:
University of Michigan
Collaborators:
Cornerstone Pharmaceuticals, Inc.
Rafael Pharmaceuticals Inc.
Treatments:
Beractant
Poractant alfa